| CD105 (Endoglin) |  |
Endoglin (CD105), a receptor for transforming growth factor ß1, is highly expressed on endothelial cells during tumor angiogenesis and inflammation with weak or negative expression in vascular endothelium of normal tissues. Several studies have found that endoglin is a more specific and sensitive angiogenesis marker than other commonly used panendothelial antibodies. Angiogenesis is controlled by angiogenic factors, mostly secreted by tumor cells. Vascular endothelial growth factor (VEGF), a 34 to 42 kd multifunctional glycosylated dimeric, is a potent angiogenic growth factor that stimulates endothelial cell proliferation and induces microvessel permeability. Studies have demonstrated a correlation between VEGF expression and vascular density. Angiogenesis has been proposed as a promising prognostic marker in a variety of tumors. Most studies of angiogenesis have been done with pan-endothelial markers such as CD31 or CD34. Endoglin is a more specific and sensitive marker for tumor angiogenesis than CD31, as it labels only newly-formed blood vessels and may serve as a prognostic marker for prostate adenocarcinoma, and cancers of the lung, stomach, and breast, and brain. CD105 may serve as a target for anti-angiogenesis therapy.
Mouse Monoclonal, Clone: MRQ-14| | 0.1 ml concentrated | 105M-14 | | | 0.5 ml concentrated | 105M-15 | | | 1 ml concentrated | 105M-16 | | | 1 ml prediluted | 105M-17 | | | 7 ml prediluted | 105M-18 | | | 5 Positive Control Slides | 105S | | |
|
Regulatory Status
|
 |
